REG - Oxford Nanopore Tech - Result of AGM; Director Responsibilities

Oxford Nanopore TechnologiesAnnouncement

10/06/2024 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240610:nRSJ8495Ra&default-theme=true

RNS Number : 8495R  Oxford Nanopore Technologies plc  10 June 2024

10 June 2024

Oxford Nanopore Technologies plc

(the "Company")

Results of Annual General Meeting; Changes to Director Roles and
Responsibilities

 

The Annual General Meeting of the Company was held earlier today. All
resolutions, as set out in the Company's Notice of Annual General Meeting
dated 30 April 2024, were passed by the appropriate majority on a
poll. Details of the poll results are set out below.

 

 

Oxford Nanopore Technologies plc Annual General Meeting Poll Results

 

 

 No.     RESOLUTION                                                                       VOTES        %       VOTES       %      VOTES        % of ISC VOTED  VOTES

FOR
AGAINST
TOTAL
WITHHELD
 1.      To receive the Directors' Report, the Audited Statement of Accounts and          469,892,189  99.99%  26,641      0.01%  469,918,830  54.46           311,222
         Auditor's Report of the Company for the financial year ended 31 December 2023

 2.      To approve the Directors' Remuneration Report for the year ended 31 December     465,905,694  99.12%  4,143,296   0.88%  470,048,990  54.48           181,062
         2023
 3.      To elect Dr Sarah Fortune as a director of the Company                           466,325,259  99.18%  3,849,452   0.82%  470,174,711  54.49           55,341
 4.      To elect Nicholas Keher as a director of the Company                             469,870,281  99.97%  162,771     0.03%  470,033,052  54.48           197,000
 5.      To elect Dr Heather Preston as a director of the Company                         466,322,469  99.21%  3,709,228   0.79%  470,031,697  54.48           198,355
 6.      To elect Katherine (Kate) Priestman as a director of the Company                 466,300,925  99.18%  3,861,923   0.82%  470,162,848  54.49           67,204
 7.      To re-elect Dr Guy Harmelin as a director of the Company                         464,917,610  98.91%  5,104,486   1.09%  470,022,096  54.47           207,956
 8.      To re-elect Adrian Hennah as a director of the Company                           460,470,500  97.94%  9,680,162   2.06%  470,150,662  54.49           79,390
 9.      To re-elect John O'Higgins as a director of the Company                          464,999,629  99.59%  1,908,185   0.41%  466,907,814  54.11           3,322,238
 10.     To re-elect Dr Gurdial (Gordon) Sanghera as a director of the Company            461,914,297  98.45%  7,270,009   1.55%  469,184,306  54.38           1,045,746
 11.     To re-elect Duncan Tatton-Brown as a director of the Company                     464,847,803  98.87%  5,309,918   1.13%  470,157,721  54.49           72,331
 12.     To appoint Deloitte LLP as auditors of the Company                               466,464,788  99.20%  3,738,930   0.80%  470,203,718  54.50           26,334
 13.     To authorise the Audit & Risk Committee to determine the remuneration of         466,575,139  99.23%  3,628,978   0.77%  470,204,117  54.50           25,935
         the auditors
 14.     To authorise the Directors to allot shares                                       460,676,251  97.98%  9,509,239   2.02%  470,185,490  54.49           44,562
 15.     To disapply pre-emption rights*                                                  464,705,201  98.83%  5,484,342   1.17%  470,189,543  54.49           40,509
 16.     To further disapply pre-emption rights*                                          445,793,600  94.81%  24,398,368  5.19%  470,191,968  54.49           38,084
 17.     To authorise the Company to make market purchases*                               469,870,163  99.94%  284,177     0.06%  470,154,340  54.49           75,712
 18.     To authorise the Company to hold any general meeting (other than an Annual       464,596,748  98.80%  5,622,100   1.20%  470,218,848  54.50           11,204
         General Meeting) on not less than 14 clear days' notice*
 19.     To authorise UK political expenditure not exceeding £100,000                     465,736,594  99.09%  4,299,448   0.91%  470,036,042  54.48           194,010

 

     *Special Resolution

 

 

 

NOTES:

 

1.   Votes "For" and "Against" are expressed as a percentage of votes
received.

 

2.   The total number of ordinary shares in issue and eligible to be voted
on at the AGM was 862,829,513.

 

3.   A "Vote withheld" is not a vote in law and is not counted in the
calculation of the percentage of shares voted "For" or "Against" any
resolution nor in the calculation of the proportion of "Total issued share
capital voted" for any resolution.

 

In accordance with Listing Rule 9.6.2, a copy of the resolutions will shortly
be submitted to the National Storage Mechanism and will be available for
inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

A copy of the poll results for the AGM will also be available shortly on the
Company's website at
https://nanoporetech.com/about-us/investors/shareholder-information
(https://nanoporetech.com/about-us/investors/shareholder-information) .

 

Director Roles and Responsibilities

 

In accordance with UK Listing Rule 9.6.11(3), the Company announces that John
O'Higgins, a Non-Executive Director, has been appointed Chair of the
Remuneration Committee on an interim basis with effect from today.

 

As previously disclosed, Tim Cowper, Dr Spike Willcocks, and Wendy Becker, the
previous Chair of the Remuneration Committee, stepped down from the Board at
the conclusion of the Company's Annual General Meeting earlier today.

 

-ENDS-

Enquiries:

Hannah Coote, Company Secretary

cosec@nanoporetech.com (mailto:cosec@nanoporetech.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFMMITMTJBBLI